SIGN UP TO CONTINUEPrint Subscriber? Sign Up for Full Access!Please sign up for as low as 36 cents per day to continue ...

After months of grueling cancer treatment, one little boy is finally back home at Fort Novosel. Months ago, before the sun ...

In the initial discovery of a drug, it can take cancer researchers up to two years to narrow down 10,000 molecules to find ...

It was hard for four-year-old Christian Sanchez to reach the Bell of Strength at city hall so the mayor offered to lift him ...

The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in first-line advanced gastric cancer with PD-L1 expression less than 1. In a 2 to 10 vote, the FDA’s ...

Lantern Pharma has won a trio of rare-pediatric-disease designations from the Food and Drug Administration for its investigational drug candidate LP-184 in multiple ultra-rare children's cancers.

and for atypical teratoid / rhabdoid tumours in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE ...

The first patient with lower-risk myelodysplastic syndromes (LR-MDS) has been dosed with RVU120 in the phase 2 REMARK study (NCT06243458). 1 "I am proud that we could start the REMARK study in line ...